Efficacy of rituximab as a single-agent therapy for the treatment of granulomatous and lymphocytic interstitial lung disease in patients with common variable immunodeficiency.
J Allergy Clin Immunol Pract
; 7(3): 1055-1057.e2, 2019 Mar.
Article
in En
| MEDLINE
| ID: mdl-30408616
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Common Variable Immunodeficiency
/
Lung Diseases, Interstitial
/
Rituximab
/
Immunologic Factors
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
En
Journal:
J Allergy Clin Immunol Pract
Year:
2019
Document type:
Article
Affiliation country:
Italy
Country of publication:
United States